UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

The lancet oncology, 2016-12, Vol.17 (12), p.1683-1696

2016

Volltextzugriff (PDF)

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

The New England journal of medicine, 2012-11, Vol.367 (22), p.2075-2088

2012

Volltextzugriff (PDF)

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma

Journal of clinical oncology, 2015-11, Vol.33 (31), p.3576-3582

2015

Volltextzugriff (PDF)

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2485-2492

2013

Volltextzugriff (PDF)

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

The New England journal of medicine, 2004-05, Vol.350 (21), p.2129-2139

2004

Volltextzugriff (PDF)

Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

Journal of clinical oncology, 2006-10, Vol.24 (29), p.4738-4745

2006

Volltextzugriff (PDF)

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

Journal of clinical oncology, 2012-01, Vol.30 (1), p.78-84

2012

Volltextzugriff (PDF)

Molecular pathogenesis of cutaneous melanocytic neoplasms

Annual review of pathology, 2009-02, Vol.4 (1), p.551-579

2009

Volltextzugriff (PDF)

Genetic Alterations in Signaling Pathways in Melanoma

Clinical cancer research, 2006-04, Vol.12 (7), p.2301s-2307s

2006

Volltextzugriff (PDF)

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

Proceedings of the National Academy of Sciences - PNAS, 2008-02, Vol.105 (8), p.3005-3010

2008

Volltextzugriff (PDF)

Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma

Journal of investigative dermatology, 2004-02, Vol.122 (2), p.337-341

2004

Volltextzugriff (PDF)

Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

The oncologist (Dayton, Ohio), 2001-02, Vol.6 (1), p.34-55

2001

Volltextzugriff (PDF)

Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma

Journal of investigative dermatology, 2006-01, Vol.126 (1), p.154-160

2006

Volltextzugriff (PDF)

Biologic Activity of Cytotoxic T Lymphocyte-Associated Antigen 4 Antibody Blockade in Previously Vaccinated Metastatic Melanoma and Ovarian Carcinoma Patients

Proceedings of the National Academy of Sciences - PNAS, 2003-04, Vol.100 (8), p.4712-4717

2003

Volltextzugriff (PDF)

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2490-2498

2017

Volltextzugriff (PDF)

Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients

Leukemia research, 2016-09, Vol.48, p.84-91

2016

Volltextzugriff (PDF)

PTEN signaling pathways in melanoma

Oncogene, 2003-05, Vol.22 (20), p.3113-3122

2003

Volltextzugriff (PDF)

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

Journal of clinical oncology, 2007-05, Vol.25 (15), p.2078-2085

2007

Volltextzugriff (PDF)

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

Clinical cancer research, 2022-04, Vol.28 (7), p.1268-1276

2022

Volltextzugriff (PDF)

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

Journal of clinical oncology, 2014-11, Vol.32 (33), p.3771-3778

2014

Volltextzugriff (PDF)

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Blood, 2016-02, Vol.127 (6), p.703-712

2016

Volltextzugriff (PDF)

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute

Melanoma research, 2005-02, Vol.15 (1), p.77-82

2005

Volltextzugriff (PDF)

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

British journal of haematology, 2013-08, Vol.162 (4), p.548-552

2013

Volltextzugriff (PDF)

1 – 25 von 151

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(145)
Mit Volltextzugriff
(141)

Publikationsform

Artikel
(149)
Buchkapitel
(2)

Sprache

Englisch
(151)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

Molecular pathogenesis of cutaneous melanocytic neoplasms

Genetic Alterations in Signaling Pathways in Melanoma

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma

Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma

Biologic Activity of Cytotoxic T Lymphocyte-Associated Antigen 4 Antibody Blockade in Previously Vaccinated Metastatic Melanoma and Ovarian Carcinoma Patients

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients

PTEN signaling pathways in melanoma

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

Suchergebnisse filtern